TIDMONC
RNS Number : 7416X
Oncimmune Holdings PLC
02 September 2020
2 September 2020
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Autoantibody profiling programme agreement signed with leading
global biopharmaceutical company
Fourth ImmunoINSIGHTS partnership agreement signed with top ten
biopharmaceutical company in under four months
Pilot programme to profile patients receiving checkpoint
inhibitor ("CPI") therapy
Oncimmune Holdings plc (AIM: ONC.L), the leading global
immunodiagnostics group, today announces it has signed an
autoantibody profiling collaboration with a leading global
biopharmaceutical company with extensive experience in developing
novel immune checkpoint inhibitors ("CPIs") (the "Agreement"). The
programme, which is scheduled to complete in Q2 2021, will evaluate
the autoantibody profiles from patient samples collected in a
clinical trial of a CPI. Such profiling is expected to enable the
biopharmaceutical partner to identify better the groups of patients
likely to both tolerate a particular CPI treatment and also those
whose disease is likely to respond positively to that
treatment.
Under the Agreement, Oncimmune will be utilising its proprietary
biomarker discovery engine, SeroTag (R) , to identify tumour
associated antibody markers that are predictive of response and
immune-related adverse events. SeroTag is a high-throughput,
multiplex technology based on one of the largest in-house protein
libraries, as well as a unique, ever-growing repository of disease
data for indications including, autoimmune diseases and cancer.
Oncimmune is helping to address a number of challenges faced by
drug developers for the successful development and broader
application of both cancer immunotherapies and treatments for
autoimmune diseases.
This is the fourth partnership agreement signed with a top ten
biopharmaceutical company in less than four months and further
demonstrates the potential of Oncimmune's unique technology and
immune expertise to assist in the development of new and safer
oncology treatments. It also underlines the success and growing
momentum of Oncimmune's partnering strategy for ImmunoINSIGHTS.
The aim of the pilot is to further validate the power of
Oncimmune's ImmunoINSIGHTS offering, ahead of signing a
significantly larger partnership agreement in profiling patients on
a range of immuno-oncology clinical trials.
Adam M Hill, CEO of Oncimmune said: "We are pleased to announce
this partnership between our ImmunoINSIGHTS business and another
world-leading biopharmaceutical company. The momentum we are
building with the world's largest companies in the pharmaceutical
industry is a testament to the value that a collaboration with
Oncimmune can bring to their development programmes. Through these
recent agreements, we look forward to further demonstrating the
potential of ImmunoINSIGHTS to have a tangible and complementary
impact on immuno-oncology clinical trial outcomes."
For further information:
Oncimmune Holdings plc
Adam Hill, Chief Executive Officer
Matthew Hall, Chief Financial Officer
contact@oncimmune.co.uk
Zeus Capital Limited (Nominated Adviser and Joint Broker)
Andrew Jones, Daniel Harris, Victoria Ayton
+44 (0)20 3829 5000
N+1 Singer (Joint Broker)
Aubrey Powell, Harry Gooden, Iqra Amin, James Fischer
+44 (0)20 7496 3000
WG Partners (Joint Broker)
David Wilson, Chris Lee
+44 (0)203 705 9321
Media enquiries:
FTI Consulting
Ben Atwell, Michael Trace, Alex Davis
Oncimmune@fticonsulting.com
+44 (0)20 3727 1000
About Oncimmune
Our intimate understanding of the human immune system enables us
to harness its sophisticated response to disease to detect cancer
earlier and to support the development of better therapies.
The key to improving cancer survival is early detection and
better selection for therapy. As a company, we are driven by our
passion to improve cancer survival and give people extra time.
Oncimmune's immunodiagnostic test, EarlyCDT, can detect and help
identify cancer on average four years earlier than standard
clinical diagnosis.
The unique combination of our core technology and understanding
of the immune system, powers our ImmunoINSIGHTS service; a
proprietary platform that enables life science organisations to
optimise drug development and delivery, leading to more effective,
targeted as well as safer treatments for patients.
Oncimmune was founded in 2002 and launched its platform
diagnostic technology in 2009, followed by the launch of its first
commercial tests, EarlyCDT Lung and EarlyCDT Liver. To date, over
200,000 tests have been performed for patients worldwide. EarlyCDT
Lung was also used in what is believed to be the largest randomised
controlled trial for the early detection of lung cancer using
biomarkers, the successful National Health Service (NHS) Early
detection of Cancer of the Lung ("ECLS") trial of 12,208 high-risk
smokers in Scotland. This trial demonstrated that EarlyCDT Lung
reduced the incidence of patients with late-stage lung cancer or
unclassified presentation at diagnosis, compared to standard
clinical practice.
Oncimmune, headquartered at its laboratory facility in
Nottingham, UK, has a discovery research centre in Dortmund,
Germany and a partner representative office in Shanghai, China.
Oncimmune joined the Alternative Investment Market (AIM) of the
London Stock Exchange in May 2016 under the ticker ONC.L.
What is ImmunoINSIGHTS?
The ImmunoINSIGHTS service business leverages Oncimmune's
technology platform and methodologies across multiple diseases, to
offer life-science organisations actionable insights for therapies
across the development and product lifecycle. Our core
immune-profiling technology is underpinned by our library of over
eight thousand immunogenic proteins, one of the largest of its
kind. This helps identify trial participants and patients into
clinically relevant subgroups, enabling development of targeted and
more effective treatments.
What is SeroTag?
Oncimmune's proprietary biomarker discovery engine, which is
leveraged in our ImmunoINSIGHTS services to discover and validate
novel biomarkers can help stratify patients in multiple cancer
indications and with different autoimmune diseases.
This high-throughput, multiplex technology is based on one of
the largest, in-house protein libraries, as well as a unique,
ever-growing repository of disease data for indications including,
but not limited to, autoimmune diseases and cancer. As a result,
SeroTag is helping to address and monitor a number of challenges
currently hindering the successful development and broader
application of both cancer immunotherapies and treatments for
autoimmune diseases.
The platform is being applied to discover and validate
biomarkers and develop precision diagnostic tools from minimally
invasive liquid biopsies. SeroTag analyses autoantibodies-some of
the most stable analytes-and is used most frequently for the
identification of IgG isoforms, in addition to IgM and IgA, from
just a few drops of serum.
The SeroTag platform acts as the primary discovery engine that
feeds into the creation of Oncimmune's NavigAID disease-specific
stratification panels-precision medicine tools which are enabling
patient and disease stratification and support therapeutic
development.
For more information, visit www.oncimmune.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGRLBMMTMTTMTBM
(END) Dow Jones Newswires
September 02, 2020 02:04 ET (06:04 GMT)
Oncimmune (LSE:ONC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2023 to Apr 2024